Cargando…
Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models
Near infrared photoimmunotherapy (NIR-PIT) is a newly developed and highly selective cancer treatment that induces necrotic/immunogenic cell death. It employs a monoclonal antibody (mAb) conjugated to a photo-absorber dye, IRDye700DX, which is activated by NIR light. Tumor-targeting NIR-PIT is also...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564971/ https://www.ncbi.nlm.nih.gov/pubmed/32937841 http://dx.doi.org/10.3390/vaccines8030528 |
_version_ | 1783595833958072320 |
---|---|
author | Maruoka, Yasuhiro Furusawa, Aki Okada, Ryuhei Inagaki, Fuyuki Fujimura, Daiki Wakiyama, Hiroaki Kato, Takuya Nagaya, Tadanobu Choyke, Peter L. Kobayashi, Hisataka |
author_facet | Maruoka, Yasuhiro Furusawa, Aki Okada, Ryuhei Inagaki, Fuyuki Fujimura, Daiki Wakiyama, Hiroaki Kato, Takuya Nagaya, Tadanobu Choyke, Peter L. Kobayashi, Hisataka |
author_sort | Maruoka, Yasuhiro |
collection | PubMed |
description | Near infrared photoimmunotherapy (NIR-PIT) is a newly developed and highly selective cancer treatment that induces necrotic/immunogenic cell death. It employs a monoclonal antibody (mAb) conjugated to a photo-absorber dye, IRDye700DX, which is activated by NIR light. Tumor-targeting NIR-PIT is also at least partly mediated by a profound immune response against the tumor. Cytotoxic T-lymphocyte antigen-4 (CTLA4) is widely recognized as a major immune checkpoint protein, which inhibits the immune response against tumors and is therefore, a target for systemic blockade. We investigated the effect of combining tumor-targeted NIR-PIT against the cell-surface antigen, CD44, which is known as a cancer stem cell marker, with a systemic CTLA4 immune checkpoint inhibitor in three syngeneic tumor models (MC38-luc, LL/2, and MOC1). CD44-targeted NIR-PIT combined with CTLA4 blockade showed greater tumor growth inhibition with longer survival compared with CTLA4 blockade alone in all tumor models. NIR-PIT and CTLA4 blockade produced more complete remission in MOC1 tumors (44%) than NIR-PIT and programmed cell death protein 1 (PD-1) blockade (8%), which was reported in our previous paper. However, the combination of NIR-PIT and CTLA4 blockade was less effective in MC38-luc tumors (11%) than the combination of NIR-PIT and PD-1 blockade (70%). Nonetheless, in many cases ineffective results with NIR-PIT and PD-1 blockade were reversed with NIR-PIT and CTLA4 blockade. |
format | Online Article Text |
id | pubmed-7564971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75649712020-10-26 Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models Maruoka, Yasuhiro Furusawa, Aki Okada, Ryuhei Inagaki, Fuyuki Fujimura, Daiki Wakiyama, Hiroaki Kato, Takuya Nagaya, Tadanobu Choyke, Peter L. Kobayashi, Hisataka Vaccines (Basel) Article Near infrared photoimmunotherapy (NIR-PIT) is a newly developed and highly selective cancer treatment that induces necrotic/immunogenic cell death. It employs a monoclonal antibody (mAb) conjugated to a photo-absorber dye, IRDye700DX, which is activated by NIR light. Tumor-targeting NIR-PIT is also at least partly mediated by a profound immune response against the tumor. Cytotoxic T-lymphocyte antigen-4 (CTLA4) is widely recognized as a major immune checkpoint protein, which inhibits the immune response against tumors and is therefore, a target for systemic blockade. We investigated the effect of combining tumor-targeted NIR-PIT against the cell-surface antigen, CD44, which is known as a cancer stem cell marker, with a systemic CTLA4 immune checkpoint inhibitor in three syngeneic tumor models (MC38-luc, LL/2, and MOC1). CD44-targeted NIR-PIT combined with CTLA4 blockade showed greater tumor growth inhibition with longer survival compared with CTLA4 blockade alone in all tumor models. NIR-PIT and CTLA4 blockade produced more complete remission in MOC1 tumors (44%) than NIR-PIT and programmed cell death protein 1 (PD-1) blockade (8%), which was reported in our previous paper. However, the combination of NIR-PIT and CTLA4 blockade was less effective in MC38-luc tumors (11%) than the combination of NIR-PIT and PD-1 blockade (70%). Nonetheless, in many cases ineffective results with NIR-PIT and PD-1 blockade were reversed with NIR-PIT and CTLA4 blockade. MDPI 2020-09-14 /pmc/articles/PMC7564971/ /pubmed/32937841 http://dx.doi.org/10.3390/vaccines8030528 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Maruoka, Yasuhiro Furusawa, Aki Okada, Ryuhei Inagaki, Fuyuki Fujimura, Daiki Wakiyama, Hiroaki Kato, Takuya Nagaya, Tadanobu Choyke, Peter L. Kobayashi, Hisataka Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models |
title | Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models |
title_full | Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models |
title_fullStr | Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models |
title_full_unstemmed | Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models |
title_short | Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models |
title_sort | near-infrared photoimmunotherapy combined with ctla4 checkpoint blockade in syngeneic mouse cancer models |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564971/ https://www.ncbi.nlm.nih.gov/pubmed/32937841 http://dx.doi.org/10.3390/vaccines8030528 |
work_keys_str_mv | AT maruokayasuhiro nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels AT furusawaaki nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels AT okadaryuhei nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels AT inagakifuyuki nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels AT fujimuradaiki nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels AT wakiyamahiroaki nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels AT katotakuya nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels AT nagayatadanobu nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels AT choykepeterl nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels AT kobayashihisataka nearinfraredphotoimmunotherapycombinedwithctla4checkpointblockadeinsyngeneicmousecancermodels |